NEW YORK (GenomeWeb) – Exosome Diagnostics said today that it has entered into an agreement with Merck KGaA, in which it will help further the company's drug development efforts.

The collaboration will cover therapeutic development in oncology and other disease areas, and will use Exosome's proprietary technology platforms for nucleic acid and protein detection from circulating exosomes, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.